LONDON, Nov. 17 /PRNewswire-FirstCall/ -- Medicsight PLC, a majority owned subsidiary of Medicsight, Inc. and a leading developer of computer-aided detection (CAD) technologies and software, announced today the promotion of Adam Boyse, former product delivery director, to the position of chief operating officer, reporting to Tim Paterson-Brown, Medicsight PLC chief executive officer. As COO, Boyse will drive operational activities in addition to the continued direction of the Company’s product development team and product pipeline.
“Adam’s contributions to the development and commercialization of our proprietary CAD software have been significant,” said Paterson-Brown. “I am particularly confident in his leadership of our product evolution strategy, which we believe will drive increased penetration of our products into the global medical imaging market.”
Boyse joined Medicsight in May 2005 after nearly 15 years in the software development sector, where he has developed a broad range of experience in markets as diverse as automotive and telecommunications. In the last five years, he has been responsible for successfully delivering more than 40 software products. Recently, he served as vice president of software development at IDBS, a market-leading life sciences software company, where he oversaw the growth of the development group and steered the company to ISO 9001 and TickIT certification.
Since joining Medicsight, Boyse has assumed responsibilities for regulatory strategy and has led development of Medicsight’s new product pipeline, allowing the products to be integrated into 3D workstations and PACS. Most recently, he guided the Company through successful quality audits, one of which resulted in the Company receiving ISO 13485:2003 registration, a set of well-accepted international quality standards for medical device manufacturers.
“I continue to be impressed with Medicsight’s strategic vision and products and look forward to continuing to work with our medical imaging experts and business partners to build a strong platform for continued business growth,” said Boyse.
Boyse will continue to work from Medicsight’s global headquarters in London.
About Medicsight
Medicsight develops enterprise-wide computer-aided detection (CAD) software that is used by the medical imaging market to aid in earlier detection of disease. Tested on one of the world’s largest databases of verified CT scan data, Medicsight’s software solutions help clinicians identify, measure, and analyze suspicious pathology, such as colorectal polyps and lung lesions. The Company’s CAD products include ColonCAD API and LungCAD API. Both products allow for a concurrent read that lets clinicians review the original image simultaneously with the Medicsight CAD findings, which results in improved workflow and productivity. Medicsight continues to develop CAD software for a variety of disease states that can help in the early detection of disease and ultimately improve patient outcomes. Headquartered in London, Medicsight employs more than 60 people and also has offices in the United States, Japan, and China. Product and company information can be found on http://www.medicsight.com . Stock symbol: OTCBB:MSHT
All forward-looking statements are made pursuant to the ‘safe harbor’ provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission. MSHTG
Medicsight, Inc.
CONTACT: media, Lindsay Vidrine of Fleishman-Hillard, +1-314-982-1723,investors, Stephanie Carrington, +1-646-536-7017, or Nick Laudico,+1-646-536-7030, both of The Ruth Group
Web site: http://www.medicsight.com/
